JP2016172739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016172739A5 JP2016172739A5 JP2016073172A JP2016073172A JP2016172739A5 JP 2016172739 A5 JP2016172739 A5 JP 2016172739A5 JP 2016073172 A JP2016073172 A JP 2016073172A JP 2016073172 A JP2016073172 A JP 2016073172A JP 2016172739 A5 JP2016172739 A5 JP 2016172739A5
- Authority
- JP
- Japan
- Prior art keywords
- diazaspiro
- thioxo
- octane
- phenyl
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- -1 pyrrolidin-2-one-yl Chemical group 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 150000001204 N-oxides Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000002552 dosage form Substances 0.000 claims 12
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 8
- 239000006186 oral dosage form Substances 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 5
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 4
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- LVWAAWKJSFHDLD-UHFFFAOYSA-N 3-methyl-5-[5-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1 LVWAAWKJSFHDLD-UHFFFAOYSA-N 0.000 claims 3
- FMYJSGCAKSIFEE-UHFFFAOYSA-N 5-[5-[2-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC(C=C1F)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S FMYJSGCAKSIFEE-UHFFFAOYSA-N 0.000 claims 3
- FOCHZLGBEJVMIG-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-morpholin-4-ylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCN1CCOCC1 FOCHZLGBEJVMIG-UHFFFAOYSA-N 0.000 claims 3
- RBSHCUVYELMIBG-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(3-pyrrolidin-1-ylpropoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCCN1CCCC1 RBSHCUVYELMIBG-UHFFFAOYSA-N 0.000 claims 3
- QYTWADPOXANMJX-UHFFFAOYSA-N 5-[5-[4-fluoro-3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCOC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1F QYTWADPOXANMJX-UHFFFAOYSA-N 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- WHYHOPOYOMDCND-UHFFFAOYSA-N 3-methyl-5-[5-[4-(oxan-4-yloxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]pyridine-2-carbonitrile Chemical compound N1=C(C#N)C(C)=CC(N2C(C3(CCC3)N(C=3C=CC(OC4CCOCC4)=CC=3)C2=S)=O)=C1 WHYHOPOYOMDCND-UHFFFAOYSA-N 0.000 claims 2
- PBPWDARAEUASIQ-UHFFFAOYSA-N 5-[5-[2-fluoro-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCOC(C=C1F)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S PBPWDARAEUASIQ-UHFFFAOYSA-N 0.000 claims 2
- HVVRFIVGBXLFMK-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-morpholin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCOCC1 HVVRFIVGBXLFMK-UHFFFAOYSA-N 0.000 claims 2
- ZZVWEKVZWXQPTE-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-methylpyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C)C(C#N)=NC=2)C=C1F ZZVWEKVZWXQPTE-UHFFFAOYSA-N 0.000 claims 2
- NWZHJVULIKUIBK-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F NWZHJVULIKUIBK-UHFFFAOYSA-N 0.000 claims 2
- DANLBLHNDJGDKM-UHFFFAOYSA-N 5-[5-[4-fluoro-3-(2-morpholin-4-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1OCCN1CCOCC1 DANLBLHNDJGDKM-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- RDEFTHKSTLWCEU-UHFFFAOYSA-N 3-(trifluoromethyl)pyridine-2-carbonitrile Chemical group FC(F)(F)C1=CC=CN=C1C#N RDEFTHKSTLWCEU-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- ZRVHHWOBMQBXSK-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-piperazin-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCNCC1 ZRVHHWOBMQBXSK-UHFFFAOYSA-N 0.000 claims 1
- LFTPCKCORZZBKJ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-(2-pyrrolidin-1-ylethoxy)phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound FC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1OCCN1CCCC1 LFTPCKCORZZBKJ-UHFFFAOYSA-N 0.000 claims 1
- KRFVGLPKICDNDQ-UHFFFAOYSA-N 5-[5-[3-fluoro-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1F KRFVGLPKICDNDQ-UHFFFAOYSA-N 0.000 claims 1
- GDINBDLWXJOGEW-UHFFFAOYSA-N 5-[5-[4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC=C(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)C=C1 GDINBDLWXJOGEW-UHFFFAOYSA-N 0.000 claims 1
- NIVRTVOACSMZEF-UHFFFAOYSA-N 5-[5-[4-fluoro-3-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile Chemical compound C1CN(C)CCN1CCOC1=CC(N2C3(CCC3)C(=O)N(C2=S)C=2C=C(C(C#N)=NC=2)C(F)(F)F)=CC=C1F NIVRTVOACSMZEF-UHFFFAOYSA-N 0.000 claims 1
- QZISHJOPEUFEBM-UHFFFAOYSA-N C1CCN(C1)CCOC2=C(C=C(C=C2)N3C(=S)NC(=O)C34CCC4)F Chemical compound C1CCN(C1)CCOC2=C(C=C(C=C2)N3C(=S)NC(=O)C34CCC4)F QZISHJOPEUFEBM-UHFFFAOYSA-N 0.000 claims 1
- WJSJOZROBWTJTJ-UHFFFAOYSA-N CN1CCN(CC1)CCOC2=C(C=CC(=C2)N3C(=S)NC(=O)C34CCC4)F Chemical compound CN1CCN(CC1)CCOC2=C(C=CC(=C2)N3C(=S)NC(=O)C34CCC4)F WJSJOZROBWTJTJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30508210P | 2010-02-16 | 2010-02-16 | |
| US61/305,082 | 2010-02-16 | ||
| US32902310P | 2010-04-28 | 2010-04-28 | |
| US61/329,023 | 2010-04-28 | ||
| US38845710P | 2010-09-30 | 2010-09-30 | |
| US61/388,457 | 2010-09-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554001A Division JP5918147B2 (ja) | 2010-02-16 | 2011-02-16 | アンドロゲン受容体モジュレーターおよびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091441A Division JP6391076B2 (ja) | 2010-02-16 | 2017-05-01 | アンドロゲン受容体モジュレーターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016172739A JP2016172739A (ja) | 2016-09-29 |
| JP2016172739A5 true JP2016172739A5 (enExample) | 2017-04-27 |
| JP6141484B2 JP6141484B2 (ja) | 2017-06-07 |
Family
ID=44483553
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554001A Expired - Fee Related JP5918147B2 (ja) | 2010-02-16 | 2011-02-16 | アンドロゲン受容体モジュレーターおよびその使用 |
| JP2016073172A Expired - Fee Related JP6141484B2 (ja) | 2010-02-16 | 2016-03-31 | アンドロゲン受容体モジュレーターおよびその使用 |
| JP2017091441A Expired - Fee Related JP6391076B2 (ja) | 2010-02-16 | 2017-05-01 | アンドロゲン受容体モジュレーターおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554001A Expired - Fee Related JP5918147B2 (ja) | 2010-02-16 | 2011-02-16 | アンドロゲン受容体モジュレーターおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017091441A Expired - Fee Related JP6391076B2 (ja) | 2010-02-16 | 2017-05-01 | アンドロゲン受容体モジュレーターおよびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9108944B2 (enExample) |
| EP (4) | EP2824102B1 (enExample) |
| JP (3) | JP5918147B2 (enExample) |
| KR (2) | KR101819199B1 (enExample) |
| CN (3) | CN106983749A (enExample) |
| AU (1) | AU2011218173C1 (enExample) |
| BR (1) | BR112012020558B1 (enExample) |
| CA (1) | CA2787083C (enExample) |
| CY (1) | CY1120297T1 (enExample) |
| DK (1) | DK3124481T3 (enExample) |
| EA (3) | EA023981B1 (enExample) |
| ES (1) | ES2668380T3 (enExample) |
| HR (1) | HRP20180848T1 (enExample) |
| HU (1) | HUE037389T2 (enExample) |
| IL (3) | IL220703A (enExample) |
| LT (1) | LT3124481T (enExample) |
| MX (2) | MX355915B (enExample) |
| PH (3) | PH12012501652A1 (enExample) |
| PL (1) | PL3124481T3 (enExample) |
| PT (1) | PT3124481T (enExample) |
| RS (1) | RS57309B1 (enExample) |
| SG (3) | SG10201907588XA (enExample) |
| SI (1) | SI3124481T1 (enExample) |
| SM (1) | SMT201800277T1 (enExample) |
| WO (1) | WO2011103202A2 (enExample) |
| ZA (2) | ZA201507865B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3124481T1 (en) | 2010-02-16 | 2018-06-29 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and their use |
| JP5833681B2 (ja) * | 2011-03-10 | 2015-12-16 | 蘇州開拓薬業有限公司Ｓｕｚｈｏｕｋｉｎｔｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アンドロゲン受容体アンタゴニストおよびその使用 |
| CN103857667A (zh) * | 2011-10-22 | 2014-06-11 | 陈德桂 | 一组乙内酰脲衍生物的组成、合成和应用 |
| EA201490897A1 (ru) | 2011-12-16 | 2015-03-31 | Олема Фармасьютикалс, Инк. | Новые бензопирановые соединения, композиции и их применение |
| AU2013208847B2 (en) | 2012-01-13 | 2017-08-31 | Aranda Pharma Ltd | Novel heteroarylamide derivatives having antiandrogenic properties |
| UY34646A (es) | 2012-03-02 | 2013-10-31 | Novartis Ag | Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos |
| SG10201610248SA (en) * | 2012-06-07 | 2017-02-27 | Aragon Pharmaceuticals Inc | Crystalline forms of an androgen receptor modulator |
| EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| CN103804358B (zh) * | 2012-11-14 | 2016-06-29 | 上海医药集团股份有限公司 | 一类二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| JP6469092B2 (ja) * | 2013-05-29 | 2019-02-13 | ヒノバ ファーマシューティカルズ インコーポレイテッド | イミダゾリジンジオン化合物及び薬物組成物 |
| WO2015018356A1 (zh) * | 2013-08-08 | 2015-02-12 | 上海医药集团股份有限公司 | 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
| CN103601671B (zh) * | 2013-10-22 | 2016-08-17 | 上海泰坦科技股份有限公司 | 碘代三氟甲基吡啶的制备方法 |
| US9682960B2 (en) * | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| CN103694243B (zh) * | 2013-12-20 | 2015-09-09 | 中国农业大学 | 2-取代吡啶基-1,2,4-三唑并[1,2-a]哒嗪化合物 |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| EP3102183A1 (en) * | 2014-02-05 | 2016-12-14 | LEK Pharmaceuticals d.d. | Solid pharmaceutical compositions of androgen receptor antagonists |
| CN104844520B (zh) * | 2014-02-13 | 2017-09-05 | 成都伊诺达博医药科技有限公司 | 一种合成恩杂鲁胺的方法 |
| CN104844521B (zh) * | 2014-02-13 | 2017-08-15 | 成都伊诺达博医药科技有限公司 | 抗前列腺癌药物恩杂鲁胺的合成方法 |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| EP4494636A3 (en) | 2014-12-05 | 2025-04-30 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| MX381829B (es) | 2014-12-05 | 2025-03-13 | Aragon Pharmaceuticals Inc | Composiciones anticancerígenas. |
| PL3226842T3 (pl) * | 2014-12-05 | 2021-07-12 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| NZ732756A (en) | 2014-12-19 | 2023-02-24 | Aragon Pharmaceuticals Inc | Processes for the preparation of a diarylthiohydantoin compound |
| CN107108507B (zh) * | 2014-12-19 | 2024-05-28 | 阿拉贡药品公司 | 制备二芳基硫代乙内酰脲化合物的方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN107428734A (zh) * | 2015-01-20 | 2017-12-01 | 阿尔维纳斯股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| CN105732575A (zh) * | 2015-02-06 | 2016-07-06 | 苏州晶云药物科技有限公司 | 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法 |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| WO2016172358A1 (en) * | 2015-04-21 | 2016-10-27 | Gtx, Inc. | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| CA3014432C (en) | 2015-06-18 | 2024-05-07 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| PE20180572A1 (es) | 2015-06-18 | 2018-04-04 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2018009694A1 (en) * | 2016-07-08 | 2018-01-11 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| AU2017316756A1 (en) | 2016-08-22 | 2019-02-21 | Janssen Pharmaceutica Nv | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
| CN108069869B (zh) * | 2016-11-09 | 2022-03-01 | 上海医药工业研究院 | 一种Apalutamide的制备方法及其中间体 |
| EP3555061B1 (en) * | 2016-12-13 | 2023-06-07 | Watson Laboratories Inc. | Solid state forms of apalutamide |
| KR102658095B1 (ko) | 2017-08-07 | 2024-04-19 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 안드로겐 수용체 길항제로서 다이아릴티오하이단토인 화합물 |
| CN109422737B (zh) * | 2017-08-22 | 2021-07-30 | 上海时莱生物技术有限公司 | 咪唑酮类雄激素受体拮抗剂、其制备方法和用途 |
| WO2019046467A1 (en) | 2017-08-29 | 2019-03-07 | Rutgers, The State University Of New Jersey | INDAZOLES THERAPEUTIC |
| CN109422725A (zh) * | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| NZ763947A (en) | 2017-10-16 | 2025-12-19 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
| US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
| US12202815B2 (en) | 2018-09-05 | 2025-01-21 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP3886853A4 (en) * | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | DIARYLHYDANTOI COMPOUNDS AND METHODS OF USE THEREOF |
| US12358913B2 (en) | 2019-02-01 | 2025-07-15 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of diarylthiohydantoin compound |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| CN110452166A (zh) * | 2019-09-06 | 2019-11-15 | 浙江朗华制药有限公司 | 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法 |
| EP4025570A4 (en) * | 2019-09-06 | 2022-11-02 | ONO Pharmaceutical Co., Ltd. | HYDANTOINDIVATIVES |
| CN115916170A (zh) | 2020-04-17 | 2023-04-04 | 埃萨制药股份有限公司 | 固体形式的n-末端结构域雄激素受体抑制剂及其用途 |
| CN113698317B (zh) * | 2020-05-20 | 2025-09-30 | 苏州科伦药物研究有限公司 | 阿帕他胺的合成方法、其中间体及合成方法 |
| CN114315805A (zh) * | 2020-10-09 | 2022-04-12 | 中国科学院上海药物研究所 | 芳环并环状内脂类硫代乙内酰脲化合物及制备方法和用途 |
| US20220380378A1 (en) * | 2021-04-22 | 2022-12-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| CN115650954A (zh) * | 2022-10-24 | 2023-01-31 | 江苏海悦康医药科技有限公司 | 阿帕他胺有关物质的制备方法 |
| WO2024088395A1 (zh) * | 2022-10-28 | 2024-05-02 | 南京明德新药研发有限公司 | 桥环类化合物及其在药学上的应用 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3823240A (en) | 1970-10-06 | 1974-07-09 | Rhone Poulenc Sa | Fungicidal hydantoin derivatives |
| GB1472467A (en) | 1974-04-19 | 1977-05-04 | Wyeth John & Brother Ltd | Thiohydantoins |
| FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
| DE2614831A1 (de) | 1976-04-06 | 1977-10-20 | Bayer Ag | 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| MC1220A1 (fr) | 1977-10-28 | 1979-07-20 | Hoffmann La Roche | Nouveaux derives d'imidazolidine |
| CA1138334A (en) | 1977-10-28 | 1982-12-28 | Karl Bernauer | Pharmaceutical preparations containing certain urea derivatives |
| ZA786739B (en) | 1977-12-01 | 1980-07-30 | Wellcome Found | Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations |
| EP0004723A1 (en) | 1978-03-30 | 1979-10-17 | Beecham Group Plc | Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them |
| FR2449448B1 (fr) | 1979-02-20 | 1983-05-27 | Inst Nat Radio Elements | Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation |
| FI801184A7 (fi) | 1979-04-24 | 1981-01-01 | F Hoffmann La Roche & Co | Menetelmä imidatsolidiini-johdannaisten valmistamiseksi. |
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| JPS57197268A (en) | 1981-05-29 | 1982-12-03 | Sumitomo Chem Co Ltd | Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient |
| DE3382406D1 (de) | 1982-04-08 | 1991-10-17 | Shell Int Research | Neue hydantoine, ihre herstellung und verwendung. |
| US4473393A (en) | 1982-08-06 | 1984-09-25 | Buffalo Color Corporation | Pesticidal thiohydantoin compositions |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| JPS59210083A (ja) | 1983-05-13 | 1984-11-28 | Otsuka Chem Co Ltd | １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤 |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| JPS6092285A (ja) | 1983-10-26 | 1985-05-23 | Shionogi & Co Ltd | イソオキサゾ−ル系環状尿素類 |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| JPH0778017B2 (ja) | 1985-12-28 | 1995-08-23 | 住友製薬株式会社 | パルス的かつ持続放出性製剤 |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| DE3604042A1 (de) | 1986-02-08 | 1987-08-13 | Hoechst Ag | Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| JPS649978A (en) | 1987-07-02 | 1989-01-13 | Shionogi & Co | Perfluoroalkylisoxazole derivative |
| US4859228A (en) | 1987-07-16 | 1989-08-22 | Ici Americas Inc | Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| FR2619381B1 (fr) | 1987-08-13 | 1989-12-08 | Roussel Uclaf | Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| CA1331757C (en) | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
| US5614620A (en) | 1988-03-30 | 1997-03-25 | Arch Development Corporation | DNA binding proteins including androgen receptor |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US6307030B1 (en) | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
| JPH0219363A (ja) | 1988-07-06 | 1990-01-23 | Fujisawa Pharmaceut Co Ltd | イミダゾリジン誘導体 |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE3835168A1 (de) | 1988-10-15 | 1990-04-19 | Bayer Ag | N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| FR2656302B1 (fr) | 1989-12-22 | 1992-05-07 | Roussel Uclaf | Nouveau procede de preparation de l'anandron et derives de l'anandron. |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| USRE35956E (en) | 1991-01-09 | 1998-11-10 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| US5411981A (en) | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| FR2693461B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5346913A (en) | 1992-05-26 | 1994-09-13 | Rohm And Haas Company | N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| FR2715402B1 (fr) | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
| EP0721944B1 (en) | 1994-07-29 | 2001-01-17 | Suntory Limited | Imidazolidine derivative and use thereof |
| FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| DE19540027A1 (de) | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
| FR2741346B1 (fr) | 1995-11-16 | 1997-12-19 | Roussel Uclaf | Nouveau procede de preparation de derives phenylimidazolidine |
| FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
| AU1063497A (en) | 1995-11-28 | 1997-06-19 | American Home Products Corporation | 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives |
| US5554607A (en) | 1995-11-28 | 1996-09-10 | American Home Products Corporation | Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis |
| TW418195B (en) | 1995-11-28 | 2001-01-11 | American Home Prod | 2-thioxo-imidazolidin-4-one derivatives |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| FR2742749B1 (fr) | 1995-12-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques |
| US6489163B1 (en) | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
| US5726061A (en) | 1996-10-08 | 1998-03-10 | Smithkline Beechum Corporation | Method of diagnosing and monitoring colorectal cancer |
| US7053263B2 (en) | 1996-10-15 | 2006-05-30 | The Regents Of The University Of California | Mouse models of human prostate cancer progression |
| KR100514941B1 (ko) | 1997-02-03 | 2005-09-15 | 다우 아그로사이언시즈 엘엘씨 | 살진균제로서 피리딘 환 상에 카복실산 유도체를 갖는 2-메톡시이미노-2-(피리디닐옥시메틸)페닐 아세트아미드 |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6506607B1 (en) | 1997-12-24 | 2003-01-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer |
| WO1999065494A1 (en) | 1998-06-15 | 1999-12-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| BR9914018A (pt) | 1998-09-22 | 2001-07-03 | Yamanouchi Pharmaceuticals Co | Derivado de cianofenila |
| EP0989122B1 (de) | 1998-09-22 | 2003-05-21 | Degussa AG | Verfahren zur Herstellung von Imidazolidin-2,4-dionen |
| WO2000026195A1 (en) | 1998-10-30 | 2000-05-11 | G.D. Searle & Co. | Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors |
| US6472415B1 (en) | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
| AU2847200A (en) | 1999-01-27 | 2000-08-18 | G.D. Searle & Co. | Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors |
| WO2001007048A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6479063B2 (en) | 1999-12-27 | 2002-11-12 | Kenneth Weisman | Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis |
| CN1209358C (zh) | 2000-05-31 | 2005-07-06 | 田边制药株式会社 | αLβ2介导细胞粘连的抑制剂 |
| US6482829B2 (en) | 2000-06-08 | 2002-11-19 | Hoffmann-La Roche Inc. | Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor |
| US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| WO2002053155A1 (en) | 2000-12-30 | 2002-07-11 | Geron Corporation | Telomerase inhibitor |
| FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
| US6710037B2 (en) | 2001-05-01 | 2004-03-23 | Schering Corporation | Method of treating androgen-dependent disorders |
| PL369337A1 (en) | 2001-10-01 | 2005-04-18 | Bristol-Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflammatory agents |
| EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| GB0200283D0 (en) | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| DE10218963A1 (de) | 2002-04-27 | 2003-11-20 | Aventis Pharma Gmbh | Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen |
| TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| EP1576131A4 (en) | 2002-08-15 | 2008-08-13 | Genzyme Corp | EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| FR2845384B1 (fr) | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
| EP1546111A2 (fr) | 2002-10-04 | 2005-06-29 | Laboratoires Fournier S.A. | Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete |
| FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| JP2004252175A (ja) | 2003-02-20 | 2004-09-09 | Kyocera Mita Corp | 現像装置、画像形成装置および現像剤の回収方法 |
| EP1636205A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
| JP4664814B2 (ja) | 2003-06-12 | 2011-04-06 | 中外製薬株式会社 | イミダゾリジン誘導体 |
| WO2004110986A1 (ja) | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | ベンズアミド誘導体又はその塩 |
| PE20050444A1 (es) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| AU2004298604B2 (en) | 2003-12-15 | 2010-09-23 | The Regents Of The University Of California | Molecular signature of the PTEN tumor suppressor |
| DE602004031881D1 (de) | 2003-12-19 | 2011-04-28 | Univ California | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
| NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
| EP1732543B1 (en) | 2004-03-15 | 2017-05-10 | PTC Therapeutics, Inc. | Tetracyclic carboline deratives for inhibiting angiogenesis |
| EP1621539A1 (en) | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| TW200612920A (en) | 2004-08-03 | 2006-05-01 | Chugai Pharmaceutical Co Ltd | Novel imidazolidine derivatives |
| CA2579886A1 (en) | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Novel imidazolidine derivative and use thereof |
| AU2007245022A1 (en) * | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| CA2608436C (en) * | 2005-05-13 | 2015-03-24 | The Regents Of The University Of California | Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders |
| FR2889189A1 (fr) * | 2005-07-28 | 2007-02-02 | Cerep Sa | Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| CN101032486B (zh) | 2006-03-08 | 2011-05-11 | 张宏 | 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂 |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| EP3100727B1 (en) * | 2006-03-27 | 2018-08-22 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| WO2008119015A2 (en) * | 2007-03-27 | 2008-10-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP2397469B1 (en) * | 2007-10-26 | 2014-12-31 | The Regents of The University of California | Diarylhydantoin compounds |
| CN102421291A (zh) | 2009-02-24 | 2012-04-18 | 梅迪维新前列腺医疗股份有限公司 | 具体的二芳基乙内酰脲和二芳基乙内酰硫脲化合物 |
| SI3124481T1 (en) * | 2010-02-16 | 2018-06-29 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and their use |
| BR112012021406B1 (pt) | 2010-02-24 | 2021-08-10 | Medivation Prostate Therapeutics Llc | Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína |
| WO2012024255A2 (en) | 2010-08-16 | 2012-02-23 | Duke University | Camkk-beta as a target for treating cancer |
| EP2709614A4 (en) | 2011-05-17 | 2015-04-15 | Takeda Pharmaceutical | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER |
| US20130045204A1 (en) | 2011-08-19 | 2013-02-21 | The University Of British Columbia | Fluorinated bisphenol ether compounds and methods for their use |
| US20130079241A1 (en) | 2011-09-15 | 2013-03-28 | Jianhua Luo | Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse |
| JP6309454B2 (ja) | 2011-11-30 | 2018-04-11 | アストラゼネカ アクチボラグ | 癌の併用処置 |
| EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
-
2011
- 2011-02-16 SI SI201131455T patent/SI3124481T1/en unknown
- 2011-02-16 EA EA201270720A patent/EA023981B1/ru unknown
- 2011-02-16 DK DK16184263.8T patent/DK3124481T3/en active
- 2011-02-16 SG SG10201907588XA patent/SG10201907588XA/en unknown
- 2011-02-16 AU AU2011218173A patent/AU2011218173C1/en not_active Ceased
- 2011-02-16 EP EP14188300.9A patent/EP2824102B1/en active Active
- 2011-02-16 US US13/579,009 patent/US9108944B2/en not_active Expired - Fee Related
- 2011-02-16 PH PH1/2012/501652A patent/PH12012501652A1/en unknown
- 2011-02-16 SM SM20180277T patent/SMT201800277T1/it unknown
- 2011-02-16 KR KR1020127023906A patent/KR101819199B1/ko not_active Expired - Fee Related
- 2011-02-16 BR BR112012020558-7A patent/BR112012020558B1/pt not_active IP Right Cessation
- 2011-02-16 EP EP18161153.4A patent/EP3357917A1/en not_active Withdrawn
- 2011-02-16 EP EP11745183.1A patent/EP2536708A4/en not_active Withdrawn
- 2011-02-16 MX MX2015009660A patent/MX355915B/es unknown
- 2011-02-16 EP EP16184263.8A patent/EP3124481B1/en active Active
- 2011-02-16 SG SG2012059945A patent/SG183302A1/en unknown
- 2011-02-16 EA EA201792046A patent/EA201792046A1/ru unknown
- 2011-02-16 SG SG10201501202TA patent/SG10201501202TA/en unknown
- 2011-02-16 CN CN201710229373.XA patent/CN106983749A/zh active Pending
- 2011-02-16 EA EA201590590A patent/EA028869B1/ru unknown
- 2011-02-16 CA CA2787083A patent/CA2787083C/en active Active
- 2011-02-16 RS RS20180649A patent/RS57309B1/sr unknown
- 2011-02-16 CN CN201180009819.9A patent/CN102884057B/zh not_active Expired - Fee Related
- 2011-02-16 JP JP2012554001A patent/JP5918147B2/ja not_active Expired - Fee Related
- 2011-02-16 PT PT161842638T patent/PT3124481T/pt unknown
- 2011-02-16 PL PL16184263T patent/PL3124481T3/pl unknown
- 2011-02-16 MX MX2012009453A patent/MX2012009453A/es active IP Right Grant
- 2011-02-16 CN CN201410012317.7A patent/CN103724322B/zh not_active Expired - Fee Related
- 2011-02-16 WO PCT/US2011/025106 patent/WO2011103202A2/en not_active Ceased
- 2011-02-16 KR KR1020187000615A patent/KR101972719B1/ko not_active Expired - Fee Related
- 2011-02-16 ES ES16184263T patent/ES2668380T3/es active Active
- 2011-02-16 HU HUE16184263A patent/HUE037389T2/hu unknown
- 2011-02-16 LT LTEP16184263.8T patent/LT3124481T/lt unknown
-
2012
- 2012-07-01 IL IL220703A patent/IL220703A/en active IP Right Grant
-
2015
- 2015-02-17 IL IL237272A patent/IL237272A/en active IP Right Grant
- 2015-02-17 IL IL23727315A patent/IL237273B/en active IP Right Grant
- 2015-03-12 US US14/656,031 patent/US9481664B2/en not_active Expired - Fee Related
- 2015-08-07 PH PH12015501737A patent/PH12015501737A1/en unknown
- 2015-08-07 PH PH12015501738A patent/PH12015501738B1/en unknown
- 2015-10-22 ZA ZA2015/07865A patent/ZA201507865B/en unknown
- 2015-10-22 ZA ZA2015/07863A patent/ZA201507863B/en unknown
-
2016
- 2016-03-31 JP JP2016073172A patent/JP6141484B2/ja not_active Expired - Fee Related
- 2016-09-09 US US15/261,041 patent/US10023556B2/en active Active
-
2017
- 2017-05-01 JP JP2017091441A patent/JP6391076B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-28 HR HRP20180848TT patent/HRP20180848T1/hr unknown
- 2018-06-06 CY CY20181100592T patent/CY1120297T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016172739A5 (enExample) | ||
| EP2139484B9 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| US8815926B2 (en) | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | |
| AU2014317119B2 (en) | Combination of a MEK inhibitor and an ERK inhibitor for use in treatment of hyperproliferative diseases | |
| US10729680B2 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP2025536259A (ja) | 三環式化合物及びその使用 | |
| JP2009529047A5 (enExample) | ||
| JP2019529484A5 (enExample) | ||
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| JP2016106112A (ja) | ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用 | |
| JP2019514878A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| JP2012524056A5 (enExample) | ||
| RU2009103810A (ru) | Новые соединения | |
| JP2007505933A5 (enExample) | ||
| JP2017527548A5 (enExample) | ||
| KR20150083833A (ko) | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법 | |
| JP2018052974A (ja) | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 | |
| JP2015500884A (ja) | 癌を治療するための低酸素活性化プロドラッグおよびｍＴＯＲ阻害剤 | |
| US20210000825A1 (en) | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | |
| JPWO2021021986A5 (enExample) | ||
| JP2023537626A (ja) | Ｂｔｋ及びその変異体の阻害剤を含む剤形組成物 | |
| CN113966329B (zh) | 作为pdl1检查点抑制剂的杂环免疫调节剂 | |
| JP2025525278A (ja) | マルチキナーゼ阻害剤、その組成物、及びそれを使用する方法 | |
| WO2011033094A1 (en) | Schedule of administration of benzazole derivatives in the treatment of leukemias |